Assistant Proffesor Kamilla Blecharz-Klin is an experimental pharmacologist and neurobiologist at the Medical University of Warsaw (Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology CePT), specializing in neuropharmacology, neurotransmission, and the cognitive effects of drugs and natural compounds. Her work focuses on animal models of memory disorders, neurodegeneration, obesity, and diabetes, integrating behavioral, neurochemical, and molecular analyses to uncover mechanisms underlying neurodevelopmental and neurotoxic effects, including those of early-life paracetamol exposure. She has authored and co-authored over 100 peer-reviewed publications in leading journals such as PLoS Pathogens, Neurotherapeutics, International Journal of Molecular Sciences, and Behavioral Brain Research. Dr. Blecharz-Klin has contributed to projects funded by the National Science Centre and the Ministry of Science and Higher Education, exploring the pro-cognitive effects of protocatechuic acid and the sphingosine-1-phosphate signaling pathway in type 2 diabetes. She also serves as Head of CBP User 0135 at the Medical University of Warsaw. An active member of the Polish Pharmacological Society (Warsaw Branch), the European Federation of Pharmacological Societies (EPHAR), the International Union of Basic and Clinical Pharmacology (IUPHAR), and the Society of Clinical Pharmacology and Therapeutics. Her collaborations span international centers incl